Evolent Health, Inc (NYSE:EVH) reported Q2 2017 earnings this Afternoon, coming in at ($0.13) per share, in-line Wall Street’s estimates of ($0.13) per Share. Revenue for the quarter came in at $107.30 million beating analyst estimates of $104.45 million
Analyst Coverage For Evolent Health, Inc (NYSE:EVH)
These are 11 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for Evolent Health, Inc (NYSE:EVH) is Buy (Score: 3.08) with a consensus target price of $30.56 , a potential (27.58% upside)Recent Insider Trading for Evolent Health, Inc (NYSE:EVH)
- On 8/3/2017 Frank J. Williams, CEO, sold 16,300 with an average share price of $23.73 per share and the total transaction amounting to $386,799.00.
- On 8/1/2017 Steve Wigginton, CEO, sold 6,000 with an average share price of $24.64 per share and the total transaction amounting to $147,840.00.
- On 7/24/2017 Thomas Peterson III, COO, sold 40,540 with an average share price of $26.00 per share and the total transaction amounting to $1,054,040.00.
- On 7/10/2017 Nicholas Mcgrane, CFO, sold 1,667 with an average share price of $25.42 per share and the total transaction amounting to $42,375.14.
- On 7/6/2017 Frank J. Williams, CEO, sold 16,300 with an average share price of $24.76 per share and the total transaction amounting to $403,588.00.
- On 7/3/2017 Steve Wigginton, CEO, sold 6,000 with an average share price of $25.07 per share and the total transaction amounting to $150,420.00.
Recent Trading for Evolent Health, Inc (NYSE:EVH) Shares of Evolent Health, Inc closed the previous trading session at 23.95 down -0.15 -0.62% with 1,044,089 shares trading hands.